|
ACTION
A Coronary disease Trial Investigating Outcome with Nifedipine GITS
 |
Author(s) |
(a) Lubsen J, Poole-Wilson PA, Pocock SJ, van Dalen FJ, Baumann J, Kirwan BA, Parker AB
(b) Poole-Wilson PA, Lubsen J, Kirwan B-A, van Dalen FJ,Wagener G, Danchin N, Just H, Fox KAA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Otterstad J-E, Seabra-Gomes R, Soler-Soler J, Weber S
|
 |
Title(s) |
(a) Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS
(b) Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial
|
|
Reference(s) |
(a) Eur Heart J 1998;19 Suppl I:I20–32
(b) Lancet 2004;364:849–57
|
|
Disease |
Coronary artery disease and stable angina pectoris
|
|
Purpose |
To assess the effect of nifedipine on clinical outcomes in patients with stable angina and without heart failure
|
|
Study design |
Randomised, double-blind, placebo-controlled
|
|
Follow-up |
Mean 4.9 years
|
|
Patients |
7665 patients (3825 nifedipine, 3840 placebo), mean age 63.5 years, with stable angina, left ventricular ejection fraction ≥ 40%, and either a history of MI, angiographic coronary artery disease but no history of MI, or a positive exercise test or perfusion defect with no history of coronary angiography or MI
|
|
Treatment regimen |
Nifedipine GITS, starting dose 30 mg once daily and increased to a maintenance dose of 60 mg once daily if tolerated, or placebo
|
|
Results |
There was no significant difference between the groups in the combined incidence of all-cause mortality, AMI, refractory angina, new overt heart failure, debilitating stroke, or peripheral revascularisation (4.60 per 100 patient-years vs 4.75 per 100 patient-years in the nifedipine and placebo groups, respectively; p = 0.54)
|
|
Comments |
This study has been the basis for a number of publications. A selection of references:
Coronary calcification
– Motro M et al, Cardiology 2007;107:165–71
Renal function
– Ruilope LM et al, J Hypertens 2007;25:1711–8
Safety
– Poole-Wilson PA et al, Cardiovasc Drugs Ther 2006;20:45–54 |
|
|
|
